1. Home
  2. CAPR vs PCYO Comparison

CAPR vs PCYO Comparison

Compare CAPR & PCYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$33.11

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Pure Cycle Corporation

PCYO

Pure Cycle Corporation

N/A

Current Price

$10.00

Market Cap

242.8M

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPR
PCYO
Founded
2005
1976
Country
United States
United States
Employees
N/A
44
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Water Supply
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
242.8M
IPO Year
2011
1995

Fundamental Metrics

Financial Performance
Metric
CAPR
PCYO
Price
$33.11
$10.00
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$41.38
N/A
AVG Volume (30 Days)
1.1M
50.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.50
EPS
N/A
0.19
Revenue
$22,270,465.00
$1,227,787.00
Revenue This Year
N/A
N/A
Revenue Next Year
$17,308.50
N/A
P/E Ratio
N/A
$53.09
Revenue Growth
N/A
171.54
52 Week Low
$4.30
$9.65
52 Week High
$40.37
$12.16

Technical Indicators

Market Signals
Indicator
CAPR
PCYO
Relative Strength Index (RSI) 71.31 35.37
Support Level $22.09 $9.90
Resistance Level $40.37 $10.65
Average True Range (ATR) 1.72 0.30
MACD 0.61 -0.05
Stochastic Oscillator 71.08 8.73

Price Performance

Historical Comparison
CAPR
PCYO

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About PCYO Pure Cycle Corporation

Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.

Share on Social Networks: